Download PDF
Thromb Haemost 1999; 81(02): 224-228
DOI: 10.1055/s-0037-1614447
Review Articles
Schattauer GmbH

Post-DDAVP Thrombocytopenia in Type 2B von Willebrand Disease Is not Associated with Platelet Consumption: Failure to Demonstrate Glycocalicin Increase or Platelet Activation

A. Casonato
,
A. Steffan
1   Immunotransfusional Service and Clinical Analysis, I.R.C.C.S., C.R.O. Aviano, Pordenone, Italy
,
E. Pontara
,
A. Zucchetto
,
C. Rossi
,
L. De Marco
1   Immunotransfusional Service and Clinical Analysis, I.R.C.C.S., C.R.O. Aviano, Pordenone, Italy
,
A. Girolami
› Author AffiliationsThis work was supported by grants from MURST (0.6-92) and the Veneto Region (Venice).
Further Information

Publication History

Received26 September 1997

Accepted after resubmission05 November 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

Thrombocytopenia is frequently reported in type 2B von Willebrand disease (vWD), and thought to be related to the abnormally high affinity of 2B von Willebrand factor (vWF) for platelet GPIb-IX. To gain an insight into the nature of this thrombocytopenia, we measured plasma glycocalicin (GC) levels (as a marker of platelet turnover), and platelet surface expression of the alpha granule protein P-selectin (as a marker of platelet activation) in 9 patients with type 2B vWD before, and in 4 patients also following the infusion of 1-desamino-8-d-arginine vasopressin (DDAVP). Three patients presented a persistent decrease of platelet counts in the resting condition. GC levels were within the normal range, regardless of the platelet counts, in all but one patient who presented, on the other hand, a normal platelet count. Moreover, platelets expressed normal amounts of P-selectin on their surface, regardless of platelet counts. These findings suggest that the thrombocytopenia observed in type 2B vWD is not due to platelet activation and subsequent consumption in circulation.

Despite a significant, albeit transient, decrease in platelet count, DDAVP did not induce an increase in plasma GC levels, nor enhance P-selectin expression. These observations indicate that the acute post-DDAVP thrombocytopenia in type 2B vWD is not related to platelet activation and consumption. We advance that the post-DDAVP 2B vWF is hemostatically more active, and able to induce agglutination but not aggregation of circulating platelets. This would explain both the prompt recovery of basal platelet counts after the post-DDAVP decrease, and the lack of reported thrombotic complications in this disorder.

Therefore, even though 2B vWF is characterized by an enhanced affinity for the platelet surface, its binding to platelet GPIb-IX in the soluble phase is not able to induce true platelet aggregation; vWF thus appears to be mainly an adhesive protein, rather than an aggregating agent.

 

  • References

  • 1 Ruggeri ZM, Ware J. Von Willebrand factor. Thromb Haemost 1992; 67: 594-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Sakariassen KS, Nievelstein PF, Coller BS, Sixma JJ. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Nature 1987; 279: 636-8.
    PubMedGoogle Scholar
  • 3 Caen JP, Nurden AT, Jeanneau C, Michel H, Tobelem G. et al. Bernard-Soulier syndrome: a new platelet glycoprotein abnormality. Its relationship with platelet adhesion to subendothelium and with the factor VIII von Willebrand protein. J Lab Clin Med 1976; 87: 586-96.
    PubMedGoogle Scholar
  • 4 De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. Von Willebrand factor interaction with the GPIIb-IIIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 1986; 77: 1272-7.
    CrossrefPubMedGoogle Scholar
  • 5 De Marco L, Mazzuccato M, De Roia D, Casonato A, Federici AB, Girolami A, Ruggeri ZM. Distinct abnormalities in the interaction of purified IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein Ib-IX and IIb-IIIa. J Clin Invest 1990; 86: 785-92.
    CrossrefPubMedGoogle Scholar
  • 6 De Marco L, Mazzuccato M, Del Ben MG, Budde U, Federici AB, Girolami A, Ruggeri ZM. Interaction of purified IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb-IIIa complex and initiates aggregation. Proc Nat Acad Sci 1987; 82: 7424-8.
    PubMedGoogle Scholar
  • 7 Saba I H, Saba SR, Dent J, Ruggeri ZM, Zimmerman TS. Type IIB Tampa: a variant of von Willebrand disease with chronic thrombocytopenia. Circulating platelet aggregates and spontaneous platelet aggregation. Blood 1985; 66: 282-6.
    PubMedGoogle Scholar
  • 8 Donner M, Holmberg L, Nilsson IM. Type IIB von Willebrand’s disease with probable autosomal recessive inheritance and presenting thrombocytopenia in infancy. Brit J Haemat 1987; 66: 349-54.
    CrossrefPubMedGoogle Scholar
  • 9 Rick ME, Williams SB, Sacher RA, McKeown LP. Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand’s disease. Blood 1987; 3: 786-9.
    PubMedGoogle Scholar
  • 10 Casonato A, Fabris F, Girolami A. Platelet aggregation and pseudothrombocytopenia induced by 1-desamino-8D-arginine vasopressin (DDAVP) in type 2B von Willebrand’s disease patient. Eur J Haematol 1990; 45: 36-42.
    PubMedGoogle Scholar
  • 11 Weiss HJ, Sussman I. I. A new von Willebrand factor variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood 1986; 68: 145-56.
    PubMedGoogle Scholar
  • 12 Holmberg L, Berbtorp E, Donner M, Nilsson IM. Von Willebrand’s disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Blood 1986; 68: 668-72.
    PubMedGoogle Scholar
  • 13 Goto S, Salomon DR, Ikeda Y, Ruggeri ZM. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995; 270: 23352-61.
    CrossrefPubMedGoogle Scholar
  • 14 Coller BS, Kalomiris E, Steinberg M, Scudder LE. Evidence that glycocalicin circulates in normal plasma. J Clin Invest 1984; 73: 794-9.
    CrossrefPubMedGoogle Scholar
  • 15 Steinberg MH, John MD, Kelton JG, Barry S, Coller MD. Plasma glycocalicin: An aid in the classification of thrombocytopenic disorders. New Engl J Med 1987; 317: 1037-42.
    CrossrefPubMedGoogle Scholar
  • 16 Beer JH, Buchi L, Steiner B. Glycocalicin: a new assay the normal plasma levels and its potential usefulness in selected disease. Blood 1994; 83: 681-92.
    PubMedGoogle Scholar
  • 17 Casonato A, De Marco L, Mazzuccato M, De Angelis V, De Roia A, Fabris F, Ruggeri ZM, Girolami A. A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand-factor platelet interaction and the presence of all von Willebrand factor multimers in plasma. Blood 1989; 74: 2028-33.
    PubMedGoogle Scholar
  • 18 Girolami A, Molaro G, Lazzarin M, Scarpa R, Brunetti A. A new congenital haemorrhagic condition due to the presence of abnormal factor X (factor X Friuli); study of a large kindred. Brit J Haematol 1970; 19: 179-92.
    CrossrefPubMedGoogle Scholar
  • 19 Casonato A, Fabris F, Vicariotto M, Girolami A. The evaluation of factor VIII antigen by means of a simple slide test. Am J Clin Path 1985; 29: 309-16.
    PubMedGoogle Scholar
  • 20 Casonato A, Sartori MT, Pontara E, Zucchetto S, Girolami A. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand’s disease with low platelet von Willebrand factor content. Blood Coag Fibrin 1992; 3: 149-53.
    CrossrefPubMedGoogle Scholar
  • 21 Handa M, Titani K, Holland LZ, Roberts JR, Ruggeri ZM. The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. J Biol Chem 1986; 261: 12579-85.
    PubMedGoogle Scholar
  • 22 Murata M, Ware J, Ruggeri ZM. Site-directed mutagenesis of a soluble recombinant fragment of platelet glycoprotein Ib-alfa demonstrating negatively charged residues involved in von Willebrand factor binding. J Biol Chem 1991; 286: 15474-80.
    PubMedGoogle Scholar
  • 23 Vicente V, Kostel PJ, Ruggeri ZM. Isolation and functional characterization of the von Willebrand factor-binding domain between residues HiS-Arg293 of the alpha-chain of glycoprotein Ib. J Biol Chem 1988; 263: 18473-9.
    PubMedGoogle Scholar
  • 24 Kunishima S, Hayashi K, Kobayashi S, Noal T, Ohno R. New enzyme-linked immunoadsorbent assay for glycocalicin in plasma. Clin Chem 1991; 37: 169-72.
    PubMedGoogle Scholar
  • 25 George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoprotein. Studies on resting and activated platelets and platelet microparticles in normal subjects, and observation in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-8.
    CrossrefPubMedGoogle Scholar
  • 26 Mazzuccato M, De Marco L, Masotti A, Pradella P, Bahous WF, Ruggeri ZM. Characterization of the initial α-thrombin interaction with glycoprotein Ibα in relation to platelet activation. J Biol Chem 1998; 273: 1880-98.
    CrossrefPubMedGoogle Scholar
  • 27 Casonato A, Sartori MT, De Marco L, Girolami A. 1-desamino-8-d-argi-nine vasopressin (DDAVP) in type IIB von Willebrand’s disease: shortenening of bleeding time and induction of variable pseudothrombocytopenia. Thromb Haemost 1990; 64: 117-20.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 De Marco L, Mazzuccato M, del Ben MG, Budde U, Federici AB, Girolami A, Ruggeri ZM. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin: role of platelet activation, fibrinogen and two distinct membrane receptors. J Clin Invest 1987; 80: 475-82.
    CrossrefPubMedGoogle Scholar
  • 29 Gralnick HR, Williams SB, McKeown LP, Rick ME, Maisonneuve P, Jeanneau C, Sultan Y. Von Willebrand’s disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest 1985; 76: 1522-9.
    CrossrefPubMedGoogle Scholar
  • 30 Mannucci PM, Ruggeri ZM, Pareti I F, Capitanio A. DDAVP: A new pharmacological approach to the management of haemophilia A and von Willebrand disease. Lancet 1977; 1: 869-72.
    PubMedGoogle Scholar
  • 31 Holmberg L, Nilsson IM, Borge L, Gunnarson M, Sjorin E. Platelet aggregation induced by 1-desamino-8-d-arginine vasopressin (DDAVP) in type IIB von Willebrand’s disease. N Engl J Med 1983; 309: 816-21.
    CrossrefPubMedGoogle Scholar
  • 32 Fowler WE, Berkowitz LR, Roberts HR. DDAVP for type IIB von Willebrand disease. Blood 1989; 74: 1859-60.
    PubMedGoogle Scholar
  • 33 Connaghan DG, Gralnick HR. Beneficial response to desmopressin in type IIB von Willebrand’s disease. Blood 1990; 76: 1659-59.
    PubMedGoogle Scholar
  • 34 Casonato A, Pontara E, Dannhauser D, Bertomoro A, Sartori MT, Zerbinati P, Girolami A. Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand’s disease. Blood Coag Fibrin 1994; 5: 959-64.
    CrossrefPubMedGoogle Scholar
  • 35 Castaman G, Rodeghiero F. Desmopressin and type 2B vWD. Haemophilia 1996; 2: 73-7.
    CrossrefPubMedGoogle Scholar
  • 36 Kyrle PA, Niessner H, Dent J, Panzer S, Brener B, Zimmerman TS, Lechner K. IIB von Willebrand’s disease: pathogenetic and therapeutic studies. Brit J Haemat 1988; 69: 55-9.
    CrossrefPubMedGoogle Scholar
  • 37 Francesconi MA, Deana R, Girolami A, Pontara E, Casonato A. Platelet aggregation induced by plasma from type IIB von Willebrand’s disease patients is associated with an increase in cytosolic Ca2+ concentration. Thromb Haemost 1993; 70: 697-701.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Francesconi MA, Casonato A, Pontara E, Dalla Via L, Girolami A, Deana R. Type IIB von Willebrand factor induces phospholipase A2 activation and cytosolic Ca2+ increase in platelets. Bioch Biophys Comm 1995; 24: 102-9.
    PubMedGoogle Scholar
  • 39 Gralnick HR, Williams S, McKeown LP, Connaghan G, Shafer B, Hansmann K, Magruder L, Vial M. Platelet activation and alpha granule secretion in type IIB von Willebrand’s disease. Brit J Haematol 1991; 79: 618-23.
    CrossrefPubMedGoogle Scholar
  • 40 Gangarosa EJ. Complications of ristocetin therapy. Lancet 1958; 1: 1179.
    PubMedGoogle Scholar
  • 41 Gangarosa EJ, Johnson TR, Harold SR. Ristocetin-induced thrombocytopenia: site and mechanism of action. Arch Intern Med 1960; 105: 107-13.
    PubMedGoogle Scholar
  • 42 Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJW, Bracke M, Sixma JJ, Vink T, de Groot PG. Functional studies on platelet adhesion with recombinant von Willebrand factor type 2B mutants R543Q and R543W under conditions of flow. Blood 1997; 89: 2766-72.
    PubMedGoogle Scholar